Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical Practice
Open Access
- 1 April 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 143 (4) , 573-578
Abstract
Objectives:. To compare next-generation sequencing (NGS) platforms with mutation-specific analysis platforms in a clinical setting, in terms of sensitiKeywords
This publication has 22 references indexed in Scilit:
- Comparison of Next-Generation Sequencing SystemsJournal of Biomedicine and Biotechnology, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- An integrated semiconductor device enabling non-optical genome sequencingNature, 2011
- Detection of low-level EGFR T790M mutation in lung cancer tissuesAPMIS, 2011
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based AssayClinical Cancer Research, 2011
- Sequencing technologies — the next generationNature Reviews Genetics, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutationsJournal of Clinical Oncology, 2008
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With ErlotinibJournal of Clinical Oncology, 2005
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 2004